AbbVie (NYSE:ABBV) announced today that it entered into a strategic alliance with iStar Medical over the MINIject device. The strategic transaction centers around helping to further develop and commercialize iStar’s MINIject minimally invasive glaucoma surgical (MIGS) device. It will also provide AbbVie with a chance to expand its eye care business through an option to […]
MIT researchers think microparticles could deliver ‘self-boosting’ vaccines
MIT researchers are touting microparticles that can deliver payloads at different points, potentially creating “self-boosting” vaccines. A new study, highlighted on the institute’s news website, demonstrates a way in which researchers could design vaccines that would need to be given just once before they “self-boost,” or essentially re-deliver the therapeutic, at a specified point in […]
Study backs One Drop’s AI-powered blood glucose forecasts in diabetes outcomes
One Drop announced today that a study of its AI-powered blood glucose forecasting technology leads to improved diabetes outcomes. New York-based One Drop published outcomes from a retrospective cohort study in the Journal of Medical Internet Research (JMIR). The study focused on indicators of glycemic control and health data logging in adults with type 2 diabetes using […]
6 drug delivery innovations you need to know
From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops. Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies. More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With […]
UnitedHealthcare to eliminate out-of-pocket costs on insulin, other prescription drugs
UnitedHealthcare announced today that it will eliminate out-of-pocket costs in standard fully insured group plans for certain prescription drugs. Insulin, among a number of drugs used to treat emergencies including severe allergic reactions, hypoglycemia, opioid overdoses, and acute asthma attacks will be included in the new standard offering. Along with insulin, epinephrine (for severe allergic […]
Data supports GI Dynamics’ type 2 diabetes treatment
GI Dynamics announced today that results from a registry for its EndoBarrier for type 2 diabetes were positive. Data from use of the EndoBarrier within the National Health Service (NHS) in the UK were presented by Dr. Robert Ryder of City Hospital (Birmingham, UK) at the American Diabetes Association Scientific Sessions last month, according to […]
Longenesis, Medtronic study says quality of life improves with insulin pumps for T1D patients
Longenesis announced today that a study on type 1 diabetes care, in partnership with Medtronic (NYSE:MDT), supports insulin pump use. Across less than three months, more than 85 patients participated in the research study aimed at providing qualitative and quantitative data on the quality of life for type 1 diabetics using insulin pumps compared to […]
Smiths Medical warns on 8 potential issues with infusion pumps
Smiths Medical issued an urgent field safety notice in Europe regarding its Medfusion 3500 and 4000 infusion pumps. The company issued the letter to notify on eight potential issues with its pumps. The issues include false alarms, unanticipated depleted battery alarms and abnormal circuit board behavior causing internal clock system failure. Additionally, issues with intermittent […]
Readout Health wins JDRF grant to evaluate handheld breath ketone monitor
Readout Health announced today that it entered into a sponsored research agreement with Washington University School of Medicine. The agreement with Washington University School of Medicine (St. Louis) includes a two-year, $360,000 research grant from JDRF to test the efficacy of the Biosense handheld breath ketone monitor in persons with type 1 diabetes during usual […]
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte for $320M
Vertex Pharmaceuticals (Nasdaq:VRTX) announced today that it agreed to acquire ViaCyte for $320 million. San Diego-based ViaCyte develops an advanced portfolio of novel stem cell-derived replacement therapies designed to provide a functional cure for patients with type 1 diabetes. Boston-based Vertex develops its own similar therapeutic for diabetes, having designed its VX-880 as a stem […]
